• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于SHG/TPEF显微镜的人工智能纤维化检测算法的开发,用于MASH中完全量化的肝纤维化评估。

Development of AI Based Fibrosis Detection Algorithm by SHG/TPEF Microscopy for Fully Quantified Liver Fibrosis Assessment in MASH.

作者信息

Akbary Kutbuddin, Noureddin Mazen, Yayun Ren, Tai Dean, Boudes Pol

机构信息

HistoIndex Pte Ltd, Singapore, Singapore.

Houston Methodist Hospital, Houston, Texas, USA.

出版信息

Liver Int. 2025 Sep;45(9):e70258. doi: 10.1111/liv.70258.

DOI:10.1111/liv.70258
PMID:40757802
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12320568/
Abstract

BACKGROUND AND AIMS

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major global cause of chronic liver disease, with the potential to progress from steatosis to metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis. Fibrosis is a key determinant of liver-related morbidity and mortality, highlighting the need for precise, reproducible assessment methods. This study aimed to develop and validate an Artificial Intelligence (AI)-based fibrosis detection algorithm using Second Harmonic Generation/Two Photon Excitation Fluorescence (SHG/TPEF) microscopy.

METHODS

The algorithm integrates SHG/TPEF microscopy, which uses ultra-fast lasers to capture intrinsic optical signals from unstained liver biopsies, with Machine Learning (ML)-based image analysis. The resulting qFibrosis model quantifies collagen morphology to generate a continuous fibrosis index.

RESULTS

A standardised workflow was established, encompassing sample acquisition, SHG/TPEF imaging, region-specific analysis and collagen feature quantification. Each step of the AI-based ML of qFibrosis algorithm used to assess and quantify liver fibrosis is described in detail in this study.

CONCLUSIONS

This AI-driven approach enables accurate, continuous quantification of liver fibrosis, overcoming the variability of traditional histopathology. The qFibrosis model has potential as a standardised tool for therapeutic evaluation and disease monitoring in MASLD/MASH, representing a significant advancement in liver fibrosis assessment.

摘要

背景与目的

代谢功能障碍相关脂肪性肝病(MASLD)是全球慢性肝病的主要病因,有可能从脂肪变性发展为代谢功能障碍相关脂肪性肝炎(MASH)和肝硬化。纤维化是肝脏相关发病率和死亡率的关键决定因素,这凸显了对精确、可重复评估方法的需求。本研究旨在开发并验证一种基于人工智能(AI)的纤维化检测算法,该算法使用二次谐波产生/双光子激发荧光(SHG/TPEF)显微镜。

方法

该算法将SHG/TPEF显微镜(利用超快激光从未染色的肝活检组织中捕获固有光学信号)与基于机器学习(ML)的图像分析相结合。由此产生的qFibrosis模型对胶原蛋白形态进行量化,以生成一个连续的纤维化指数。

结果

建立了一个标准化工作流程,包括样本采集、SHG/TPEF成像、区域特异性分析和胶原蛋白特征量化。本研究详细描述了用于评估和量化肝纤维化的qFibrosis算法基于AI的ML的每一步。

结论

这种由AI驱动的方法能够对肝纤维化进行准确、连续的量化,克服了传统组织病理学的变异性。qFibrosis模型有潜力作为MASLD/MASH治疗评估和疾病监测的标准化工具,代表了肝纤维化评估的重大进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7215/12320568/71ebce126642/LIV-45-0-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7215/12320568/bd74d5c8c65e/LIV-45-0-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7215/12320568/fcc7a0d234e4/LIV-45-0-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7215/12320568/c8cdaba156b3/LIV-45-0-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7215/12320568/9cbcb8cfc554/LIV-45-0-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7215/12320568/71ebce126642/LIV-45-0-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7215/12320568/bd74d5c8c65e/LIV-45-0-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7215/12320568/fcc7a0d234e4/LIV-45-0-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7215/12320568/c8cdaba156b3/LIV-45-0-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7215/12320568/9cbcb8cfc554/LIV-45-0-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7215/12320568/71ebce126642/LIV-45-0-g002.jpg

相似文献

1
Development of AI Based Fibrosis Detection Algorithm by SHG/TPEF Microscopy for Fully Quantified Liver Fibrosis Assessment in MASH.基于SHG/TPEF显微镜的人工智能纤维化检测算法的开发,用于MASH中完全量化的肝纤维化评估。
Liver Int. 2025 Sep;45(9):e70258. doi: 10.1111/liv.70258.
2
Effect of liver biopsy size on MASLD fibrosis assessment by second-harmonic generation/two-photon excitation fluorescence microscopy.肝活检大小对通过二次谐波产生/双光子激发荧光显微镜评估代谢相关脂肪性肝病纤维化的影响。
JHEP Rep. 2025 May 8;7(8):101449. doi: 10.1016/j.jhepr.2025.101449. eCollection 2025 Aug.
3
The emerging role of second harmonic generation/two photon excitation for precision digital analysis of liver fibrosis in MASH clinical trials.二次谐波产生/双光子激发在MASH临床试验中对肝纤维化进行精确数字分析的新作用。
J Hepatol. 2025 Apr 30. doi: 10.1016/j.jhep.2025.04.026.
4
Delicate and thin fibrous septa indicate a regression tendency in metabolic dysfunction-associated steatohepatitis patients with advanced fibrosis.纤细的纤维间隔提示晚期纤维化的代谢功能障碍相关脂肪性肝炎患者有消退倾向。
Hepatol Int. 2025 Feb;19(1):166-180. doi: 10.1007/s12072-024-10719-w. Epub 2024 Aug 16.
5
Repeatability and Reproducibility of Artificial Imaging-based Digital Pathology for the Evaluation of Liver Fibrosis.基于人工成像的数字病理学评估肝纤维化的重复性和再现性
Clin Gastroenterol Hepatol. 2025 Jul 30. doi: 10.1016/j.cgh.2025.06.042.
6
Extracellular vesicles as biomarkers for metabolic dysfunction-associated steatotic liver disease staging using explainable artificial intelligence.使用可解释人工智能将细胞外囊泡作为代谢功能障碍相关脂肪性肝病分期的生物标志物
World J Gastroenterol. 2025 Jun 14;31(22):106937. doi: 10.3748/wjg.v31.i22.106937.
7
Multiparametric ultrasound for non-invasive assessment of liver steatosis, fibrosis, and inflammation in metabolic dysfunction-associated steatotic liver disease.多参数超声用于代谢功能障碍相关脂肪性肝病中肝脂肪变性、纤维化和炎症的无创评估
World J Gastroenterol. 2025 Jul 7;31(25):105518. doi: 10.3748/wjg.v31.i25.105518.
8
ACMSD inhibition corrects fibrosis, inflammation, and DNA damage in MASLD/MASH.ACMSD抑制可纠正代谢相关脂肪性肝病/非酒精性脂肪性肝炎中的纤维化、炎症和DNA损伤。
J Hepatol. 2025 Feb;82(2):174-188. doi: 10.1016/j.jhep.2024.08.009. Epub 2024 Aug 22.
9
Utility of AI digital pathology as an aid for pathologists scoring fibrosis in MASH.人工智能数字病理学在协助病理学家对MASH中的纤维化进行评分方面的效用。
J Hepatol. 2025 May;82(5):898-908. doi: 10.1016/j.jhep.2024.11.032. Epub 2024 Nov 28.
10
Evaluation of the prevalence of MASLD, MASH and liver fibrosis in a Dutch bariatric cohort.荷兰肥胖症队列中代谢功能障碍相关脂肪性肝病(MASLD)、非酒精性脂肪性肝炎(MASH)和肝纤维化患病率的评估。
PLoS One. 2025 Jun 24;20(6):e0324813. doi: 10.1371/journal.pone.0324813. eCollection 2025.

本文引用的文献

1
Second-Harmonic Generated Quantifiable Fibrosis Parameters Provide Signatures for Disease Progression and Regression in Nonalcoholic Fatty Liver Disease.二次谐波产生的可量化纤维化参数为非酒精性脂肪性肝病的疾病进展和消退提供特征。
Clin Pathol. 2023 Mar 26;16:2632010X231162317. doi: 10.1177/2632010X231162317. eCollection 2023 Jan-Dec.
2
Reliable computational quantification of liver fibrosis is compromised by inherent staining variation.可靠的肝纤维化计算量化受到固有染色变化的影响。
J Pathol Clin Res. 2021 Sep;7(5):471-481. doi: 10.1002/cjp2.227. Epub 2021 Jun 2.
3
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials.
肝活检评估的可靠性欠佳对随机临床试验有影响。
J Hepatol. 2020 Dec;73(6):1322-1332. doi: 10.1016/j.jhep.2020.06.025. Epub 2020 Jun 28.
4
qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis.qFIBS:一种用于非酒精性脂肪性肝炎患者纤维化、炎症、气球样变和脂肪变性定量评估的自动化技术。
Hepatology. 2020 Jun;71(6):1953-1966. doi: 10.1002/hep.30986. Epub 2020 May 7.
5
Second harmonic generation microscopy provides accurate automated staging of liver fibrosis in patients with non-alcoholic fatty liver disease.二次谐波产生显微镜为非酒精性脂肪性肝病患者的肝纤维化提供了准确的自动分期。
PLoS One. 2018 Jun 20;13(6):e0199166. doi: 10.1371/journal.pone.0199166. eCollection 2018.
6
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.非酒精性脂肪性肝病、非酒精性脂肪性肝炎及相关纤维化的诊断方法。
Hepatology. 2018 Jul;68(1):349-360. doi: 10.1002/hep.29721.
7
Second Harmonic Generation Reveals Subtle Fibrosis Differences in Adult and Pediatric Nonalcoholic Fatty Liver Disease.二次谐波产生揭示成人和儿童非酒精性脂肪性肝病中细微的纤维化差异。
Am J Clin Pathol. 2017 Nov 20;148(6):502-512. doi: 10.1093/ajcp/aqx104.
8
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.非酒精性脂肪性肝病和非酒精性脂肪性肝炎的全球负担:趋势、预测、危险因素和预防。
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20. doi: 10.1038/nrgastro.2017.109. Epub 2017 Sep 20.
9
Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.纤维化分期而非 NASH 可预测经活检证实的非酒精性脂肪性肝病患者的死亡率和严重肝脏疾病的发生时间。
J Hepatol. 2017 Dec;67(6):1265-1273. doi: 10.1016/j.jhep.2017.07.027. Epub 2017 Aug 10.
10
Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis.基于双光子显微镜的纤维化相关参数定量分析(q-FP)用于模拟脂肪性肝炎的疾病进展。
Hepatology. 2017 Jun;65(6):1891-1903. doi: 10.1002/hep.29090. Epub 2017 Apr 28.